Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk Ventilation 3% Weaning from intubation 20% ICU time 10% Hospitalization time 3% c19early.org/d Bilir et al. Vitamin D for COVID-19 ICU PATIENTS Favors vitamin D Favors control
Does Vitamin D Supplementation Reduce Cytokine Storm and Mortality in Geriatric Intensive Care Patients Diagnosed with COVID-19
Bilir et al., Journal of Contemporary Medicine, doi:10.16899/jcm.990057
1 Jan 2022    Source   PDF   Share   Tweet
Retrospective 80 elderly ICU patients in Turkey, 40 with vitamin D levels <30ng/ml received vitamin D treatment, showing no significant differences in outcomes. Although not statistically significant, results favored treatment which suggests that supplemention was beneficial because low vitamin D levels are typically associated with worse results.
risk of death, 23.1% lower, RR 0.77, p = 0.26, treatment 20 of 40 (50.0%), control 26 of 40 (65.0%), NNT 6.7.
risk of mechanical ventilation, 3.3% lower, RR 0.97, p = 1.00, treatment 29 of 40 (72.5%), control 30 of 40 (75.0%), NNT 40.
risk of no weaning from intubation, 20.4% lower, RR 0.80, p = 0.13, treatment 20 of 29 (69.0%), control 26 of 30 (86.7%), NNT 5.6.
ICU time, 10.3% lower, relative time 0.90, p = 0.44, treatment 40, control 40.
hospitalization time, 2.9% lower, relative time 0.97, p = 0.98, treatment 40, control 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in meta analysis: control group formed from patients with high vitamin D levels.
Bilir et al., 1 Jan 2022, retrospective, Turkey, peer-reviewed, 7 authors, study period March 2021 - July 2021, dosage 50,000IU days 1, 8.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit